 WALTHAM, Mass., Sept. 09, 2021 GLOBE NEWSWIRE -- Repligen Corporation NASDAQ:RGEN, a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH Navigo, today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins. Named NGL-Impact A Hi pH, the new ligand is the first to address antibody aggregation in low pH elution buffers. While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for platform use due to its broad pH operating range. 